Dr. Zotalis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
310 Sullivan Way
Ewing, NJ 08628
Summary
- Dr. Zotalis is Board-Certified in Internal Medicine & Anatomic Pathology. After receiving his medical degree from Aristotle University of Thessaloniki School of Medicine, he trained at the University of Rochester Medical Center and Geisinger Medical Center. He brings 30+ years of clinical expertise in diverse clinical settings. His work has been presented at national meetings. He has 7 peer-reviewed publications and 150+ citations. In 2018 he joined NJM.
Education & Training
Geisinger Health System (Danville)Residency, Internal Medicine, 2007 - 2010
University of RochesterResidency, Pathology-Anatomic and Clinical, 1993 - 1998
Aristotle University of Thessaloniki School of MedicineClass of 1986
Certifications & Licensure
PA State Medical License 1998 - 2026
NJ State Medical License 2018 - 2025
VA State Medical License 2002 - 2008
WV State Medical License 2002 - 2003- American Board of Internal Medicine Internal Medicine
- American Board of Pathology Anatomic Pathology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Publications & Presentations
PubMed
- 18 citationsMorphoproteomic confirmation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer.Robert E. Brown, George Zotalis, Ping L. Zhang, Bihong Zhao
International Journal of Clinical and Experimental Pathology. 2008-01-01 - 61 citationsNFkappaB: a pivotal transcription factor in prostate cancer metastasis to bone.Valentine B Andela, Andrew H. Gordon, George Zotalis, Randy N. Rosier, J. Jeffrey Goater
Clinical Orthopaedics and Related Research. 2003-10-01 - 44 citationsThe CD44 receptor is a molecular predictor of survival in ovarian cancer.Lorna Rodriguez-Rodriguez, I. Sancho-Torres, C. Mesonero, D. G. Gibbon, Weichung Joe Shih
Medical Oncology. 2003-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
